Funding for this research was provided by:
Guy's and St Thomas' Charity
Received: 1 May 2020
Accepted: 13 September 2020
First Online: 7 October 2020
Ethics approval and consent to participate
: Ethical approval was granted by NHS Health Research Authority, Camberwell St Giles Research Ethics Committee. REC Reference 15/LO/0057. Written informed consent was obtained from all participants.
: Not applicable.
: MH2 reported grants from Innovative Medicines Initiative and European Federation of Pharmaceutical Industries and Associations, outside the submitted work. MH2 is principal investigator of RADAR-CNS (Remote Assessment of Disease and Relapse) a pre-competitive public-private partnership funded by European Commission and Janssen, Biogen, UCB, MSD and Lundbeck. TC received ad hoc payments for conducting workshops on evidence-based treatments for persistent physical symptoms. TC has received grants from NIHR programme grants, HTA, RfPB, Guy’s and St Thomas Charity, King’s Challenge Fund. Personal financial interests: TC is the author of several self-help books on chronic fatigue and received royalties in the past. TC received expenses for workshops on evidence-based treatments for persistent physical symptoms for BABCP and IAPT services (travel and accommodation).RMM reports grants from NIHR programme grants, grants from MS Society UK, grants from Crohn's and Colitis UK, grants from Breast Cancer Now, grants from National MS society, grants from NIHR HTA grants, personal fees from National Advisor to NHS England for Increasing Access to Psychological Therapies (IAPT) for People with Long Term Conditions from 2011-2016, personal fees from Ad hoc payments for workshop training, personal fees from Consultancy payments from Mahana therapeutics, other from Travel expenses to present invited talks to conferences WBCBT, ICBM, ECTRIMS, EHPS, ARPH, outside the submitted work; and King's College London has signed a license agreement with Mahana Therapeutics for a digital version of CBT for Irritable Bowel Syndrome that was developed by RMM and colleagues at Southampton and King’s College London. RMM and other inventors are beneficiaries of this license through contracts with their respective universities.SL has received grants from NIHR, MRC, ESRC, Wellcome Trust, Stanley Medical Research, MND and ALS Associations, Parkinson Disease Society, Psychiatry Research Trust, KCL Translational Research, PPP Healthcare Medical Trust and Johnson and Johnson.